As covered in the BioProcessBlog, BPTC's first bioPULSE survey found that the market was bullish on the prospects of antibody drug conjugates (ADCs) to become a major therapeutic area going forward.
Key findings in the web-based survey included:
- 83% of respondents expect to see a signifcant increase in the number of ADCs entering the pipeline in the next 5 years
- 24% indicated that they were not currently working on ADCs but expected to be doing so soon
- 24% indicated that they were already working on ADCs
- 95% of respondents said ADCs would be as big as mAbs or very important but not quite as big as mAbs (only 5% felt it was a niche application)
Conjugation technology and linker chemistry was seen to be the biggest challenge. Survey participants cited this as an opportunity for CROs/CMOs who could provide help with conjugation and linkers and provide manufacturing. See Big Red Biotech posts here and here.
Posted by Bruce Lehr Dec 16th 2011.